US Stock MarketDetailed Quotes

ACRV Acrivon Therapeutics

Watchlist
  • 5.470
  • -0.630-10.33%
Close Jan 10 16:00 ET
170.32MMarket Cap-2.06P/E (TTM)

About Acrivon Therapeutics Company

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.

Company Profile

SymbolACRV
Company NameAcrivon Therapeutics
Listing DateNov 15, 2022
Issue Price12.50
Founded2018
CEOMr. Peter Blume-Jensen, M.D.,PhD
MarketNASDAQ
Employees61
Fiscal Year Ends12-31
Address480 Arsenal Way,Suite 100
CityWatertown
ProvinceMassachusetts
CountryUnited States of America
Zip Code02472
Phone1-617-207-8979

Company Executives

  • Name
  • Position
  • Salary
  • Peter Blume-Jensen, M.D.,PhD
  • Chairman of the Board, President and Chief Executive Officer
  • 6.47M
  • Dr. Kristina Masson, M.B.A.,PhD
  • Executive Vice President, Business Operations and Director; President, Chief Executive Officer and Site Head of Acrivon AB
  • 739.78K
  • Rasmus Holm-Jorgensen
  • Chief Financial Officer and Principal Accounting Officer
  • --
  • Dr. Eric Devroe, PhD
  • Chief Operating Officer
  • --
  • Mary-Alice Miller
  • Chief Legal Officer
  • 697.00K
  • Jean-Marie Cuillerot
  • Chief Medical Officer
  • --
  • Dr. Erick Gamelin, M.D.,PhD
  • Chief Development Officer
  • --
  • Dr. Ivana Magovcevic-Liebisch, J.D.,PhD
  • Director
  • --
  • Dr. Santhosh Palani, C.F.A.
  • Director
  • --
  • Dr. Derek DiRocco, PhD
  • Independent Director
  • 65.00K
  • Michael J. Tocek, M.B.A.
  • Independent Director
  • 68.13K
  • Dr. Sharon Shacham, M.B.A.,PhD
  • Independent Director
  • 58.13K
  • Dr. Charles M. Baum, M.D.,PhD
  • Independent Director
  • 325.07K
Heat List
US
Overall
Symbol
Price
% Chg

No Data